Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri ®

Condition:   Relapsing-Remitting Multiple Sclerosis (RRMS) Intervention:   Biological: Intravenous (IV) infusions Sponsor:   Polpharma Biologics S.A. Not yet recruiting

Source: ClinicalTrials.gov - October 4, 2019 Category: Research Source Type: clinical trials